Handelsbanken Fonder AB Boosts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Handelsbanken Fonder AB raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,200 shares of the company's stock after acquiring an additional 10,400 shares during the period. Handelsbanken Fonder AB owned about 0.44% of Krystal Biotech worth $15,284,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at $2,429,000. Commonwealth Equity Services LLC increased its position in shares of Krystal Biotech by 2.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company's stock valued at $513,000 after purchasing an additional 110 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Krystal Biotech by 1.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 98,220 shares of the company's stock valued at $11,394,000 after purchasing an additional 1,604 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Krystal Biotech by 11.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,487 shares of the company's stock valued at $520,000 after purchasing an additional 452 shares during the last quarter. Finally, Strs Ohio increased its position in shares of Krystal Biotech by 120.7% during the 3rd quarter. Strs Ohio now owns 6,400 shares of the company's stock valued at $742,000 after purchasing an additional 3,500 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on KRYS shares. HC Wainwright reaffirmed a "buy" rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Citigroup boosted their price objective on Krystal Biotech from $160.00 to $195.00 and gave the company a "buy" rating in a research note on Tuesday, February 27th. Stifel Nicolaus restated a "buy" rating and issued a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Guggenheim boosted their price objective on Krystal Biotech from $130.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, February 27th. Finally, William Blair restated an "outperform" rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $171.00.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 5,000 shares of the business's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the transaction, the chief accounting officer now owns 12,936 shares of the company's stock, valued at $2,145,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 5,000 shares of the business's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the transaction, the chief accounting officer now owns 12,936 shares of the company's stock, valued at $2,145,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Price Performance

Shares of KRYS traded down $2.99 during midday trading on Wednesday, hitting $159.05. 237,973 shares of the company traded hands, compared to its average volume of 367,819. The stock has a 50-day moving average of $162.61 and a 200-day moving average of $131.15. Krystal Biotech, Inc. has a one year low of $82.09 and a one year high of $189.97. The firm has a market cap of $4.53 billion, a P/E ratio of 1,988.37 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same quarter in the prior year, the company earned ($1.25) earnings per share. Sell-side analysts forecast that Krystal Biotech, Inc. will post 1.89 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).